Officer/Director Transaction - Avalo Therapeutics, Inc. (AVTX)

On March 28, 2026, Aaron Kantoff, a director at Avalo Therapeutics, Inc., acquired 3,166 shares of Common Stock through the conversion of 3,166 Restricted Stock Units. This transaction was part of a grant awarded on August 13, 2024, with vesting scheduled over three years. Following this transaction, Mr. Kantoff directly owns 6,333 shares of Common Stock. The conversion of Restricted Stock Units into Common Stock occurred on a one-for-one basis, with no cost associated with the transaction as indicated by a price per share of $0.0.